Ergomed logo

ERGO - Ergomed News Story

788p 18.0  2.3%

Last Trade - 23/09/20

Mid Cap
Market Cap £381.5m
Enterprise Value £372.7m
Revenue £68.3m
Position in Universe 586th / 1807

Ergomed plc - Change of auditor

Mon 16th July, 2018 5:31pm
RNS Number : 8031U
Ergomed plc
16 July 2018



                                                                                                    16 July 2018


Notification re Change of Auditors


Ergomed plc ("Ergomed" or the "Company")


At the Company's Annual General Meeting held on 12 June 2018, a resolution to appoint KPMG as Ergomed's auditors was proposed and approved by shareholders.


Ergomed now announces that on 13 July 2018 it wrote to shareholders explaining that, as planned, Deloitte LLP had resigned as auditor and KPMG had been appointed as the Company's new auditor. And as required by the Companies Act the Company also sent to shareholders a statement of Deloitte's reasons for their ceasing to hold office (namely that the directors of Ergomed have decided to appoint another firm as auditors).


This announcement is being made pursuant to the requirements of AIM Rule 20.




Ergomed plc

   Tel: +44 (0) 1483 503 205

Stuart Jackson (Chief Financial Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

N+1 Singer

Tel: +44 (0) 20 7496 3000

Aubrey Powell (Joint Broker)

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Olivia Manser

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke



About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.